Member Info for Laura2022

Of course it's a discussion board but OBD must have seriously irked you considering you've done about 100 posts here but only 2 or 3 on CPX

NU

It's fascinating that you've posted x 8 times here than on any other share ..even ones you own????

They've also stated out options as I've posted below

You were buying a £80mln valued company at 53p that has no real revenues and was guzzling cash during its commercialisation phase

That's poor due diligence

That explains your anger and bitterness

I'd rather have a less than 2p average than buying at 53p for a company that basically had no revenues!!!

That's a mistake on your part

As I assume this "review" will likely take till Q1 2025

the review will consider a range of potential actions, including but not limited to a licensing or sale of Company assets - such as the EpiSwitch NST and EpiSwitch SCB tests - and a possible hive-off of the Company's US business into a separately funded entity

Therefore my plan is give my holdings 2mths+ and see what news comes out Oct/Nov /early Dec

Given they are still doing audit in January and not before suggests they must (hopefully ) have a plan for after Jan 2025

Company expects to publish preliminary results for the year ended 30 September 2024 in January 2025, following the financial audit. A further commercial update on the first quarter of the 2025 financial year will be provided at that time.

404x

All your points are and have been valid i just don't understand why you don't apply this level of critical thinking to shares you DO/WANT to own?

404x

I've asked before but do you actually OWN any investments?

All I can see on THG OBD etc is that you just go around ambulance chasing?

For context

Other bios

GDR ceo gets £270k and delivered about £100k revnue 2023 and £5mln losses

SNG even worse

Countless other biontech

Fair play to Pete S

By international work do you mean online Vegas casino ?

Porky

David Budd at GDR gets £270k!!

And yet you talk about salaries here

Puts into context how alligned and modest PYC directors are

They have often said that this is their "allignment" and share purchases on quite modest salaries are difficult

To be fair Pete is only getting 1/5th of average CEO salary

the median salary for CEOs in 2023 was £363,100 - an increase of 5.4% per annum over the past three years, and an uplift of 4.9% from 2022 when the median salary was £346,000.”

( BDO AIM 100 Directors’ Remuneration Report 2024.)

https://www.bdo.co.uk/getmedia/77317e29-8c3e-4e0b-b5af-f063a4b17829/BDO-AIM-100-Directors-Remuneration-Report-

Wonder if (probably unlikely) the timing of Monday is linked to EUDA which he may have been party to?

Would be strange to do a presentation so soon after the last Q and A without something specific to talk about in terms of "future direction "

Again, the commercial opportunity and our view of the expected market positioning for EpiSwitch PSE is addressed later in this note.

Development pipeline: two near-term prospects

There are six test programmes within the development pipeline (Exhibit 6). Two of these, EpiSwitch NST, for colorectal cancers, and EpiSwitch SCB, for the most common canine cancers, are ready for partnering or out-licensing with appropriate specialised players. Earlier programmes include both a diagnostic and a prognostic test for Amyotrophic Lateral Sclerosis (ALS), also known more generally as Motor Neurone Disease (MND), that was evaluated alongside Mitsubishi Tanabe Pharma America’s Radicava (edaravone) study programmes.

Earlier still are three programmes: rheumatoid arthritis, looking at predicting likely methotrexate responders and flaring/residual disease monitoring; metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH), looking at early detection using a simple blood test screen; and breast cancer, a screening test for earlier detection of disease across multiple groups. Broader potential applications of the EpiSwitch platform include the incorporation of existing (eg EpiSwith CiRT) or future diagnostic tests by drug developers as part of their clinical development programmes with the aim of developing companion diagnostic tests, or leveraging OBD’s proprietary biomarker data with artificial intelligence/machine learning (AI/ML) approaches to identify actionable insights. OBD is already active in the former area and will shortly start running CiRT tests on blood samples from endometrial cancer patients enrolled in a clinical trial of an undisclosed immune checkpoint inhibitor as part of an agreement with a top ten pharma company

The Group will also shortly begin running CiRT tests on blood samples from patients enrolled in a clinical trial of an immune checkpoint inhibitor in endometrial cancer, for a top 10 pharma company.

Thanks Kong

I think we all understand your position over the last 4 weeks

Which shares ARE YOU invested in ?

Post of the year

The thinly veiled irony is touching

:)

Given the post was 02.57am on a Friday night /Saturday morning I'm assuming it was the drink talking